Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 22, Issue 13, pp. 3227-3237
PubMed
Published By
Print ISSN
Online ISSN
History
- Received March 17, 2015
- Revision received January 20, 2016
- Accepted January 26, 2016
- Published first February 3, 2016.
Article Versions
- Previous version (February 3, 2016 - 09:05).
- Previous version (March 21, 2016 - 06:19).
- Previous version (April 22, 2016 - 08:10).
- You are viewing the most recent version of this article.
Copyright & Usage
©2016 American Association for Cancer Research.
Author Information
- Patricia M. LoRusso1,*,
- Jing Li1,
- Angelika Burger1,
- Lance K. Heilbrun1,
- Edward A. Sausville2,
- Scott A. Boerner1,
- Daryn Smith1,
- Mary Jo Pilat1,3,
- Jie Zhang1,
- Sara M. Tolaney4,
- James M. Cleary4,
- Alice P. Chen5,
- Lawrence Rubinstein5,
- Julie L. Boerner1,
- Adam Bowditch1,
- Dongpo Cai4,
- Tracy Bell4,
- Andrew Wolanski4,
- Allison M. Marrero6,
- Yiping Zhang6,
- Jiuping Ji6,
- Katherine Ferry-Galow6,
- Robert J. Kinders6,
- Ralph E. Parchment6, and
- Geoffrey I. Shapiro4
- 1Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
- 2University of Maryland Greenebaum Cancer Center, Baltimore, Maryland.
- 3Wayne State University, Detroit, Michigan.
- 4Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
- 5Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.
- 6Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
- ↵*Corresponding Authors:
Patricia M. LoRusso, Yale University, WWW217, 333 Cedar Street, New Haven, CT 06510. Phone: 203-785-5944; Fax: 203-785-4116; or Geoffrey I. Shapiro, Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Mayer 446, Boston, MA 02215. Phone: 617-632-4942; Fax: 617-632-1977; E-mail: geoffrey_shapiro{at}dfci.harvard.edu
July 2016
Volume 22, Issue 13
Volume 22, Issue 13
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Jump to section
Advertisement